PEG2000-C-DMG

PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA[1][2].

Product Specifications

CAS Number

1443687-74-8

UNSPSC

12352211

Target

Liposome

Type

Oligonucleotides

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/peg2000-c-dmg.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCCCC(O[C@@H](COC(NCCCOCCOC)=O)COC(CCCCCCCCCCCCC)=O)=O.[45]

Molecular Formula

C126H249NO52

Molecular Weight

2610.29

References & Citations

[1]Garber K. Alnylam launches era of RNAi drugs. Nat Biotechnol. 2018;36 (9) :777-778. |[2]Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379 (1) :11-21.